Scientists at Inventisbio Co. Ltd. and Inventisbio LLC have synthesized phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of cancer, PIK3CA-related overgrowth spectrum (PROS) and congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities (CLOVES syndrome).
Arvinas Operations Inc. has disclosed proteolysis targeting chimera (PROTAC) compounds consisting of a cereblon E3 ubiquitin ligase binding moiety coupled to a Raf kinase B G466V and/or V600E mutant targeting agent through a linker.
Caris Discovery, the therapeutic research arm of Caris Life Sciences Inc., has established a multiyear strategic partnership with Merck KGaA to accelerate the discovery and development of first-in-class antibody-drug conjugates for cancer patients.
Aethon Therapeutics Inc. has entered into a collaboration agreement with Revolution Medicines Inc. under which Aethon will use its Hapimmune platform to discover novel bispecific antibodies to mount an immune attack directed towards cancer cells hit by Revolution Medicines’ RAS(ON) inhibitors.
Bladder cancer is among the top 10 malignant tumors, still with a high mortality rate. There is a need for reliable biomarkers for early diagnosis of the disease. Proximity extension analysis (PEA) is a method that uses a quantitative PCR readout to analyze protein levels in plasma in longitudinal studies and genomic association studies.
Positive updated phase II data with CAN-2409 in pancreatic cancer led shares of Candel Therapeutics Inc. (NASDAQ:CADL) to close April 4 at $6.40, up $4.72, or 281%, well above the firm’s previous 52-week high. At one point during the day, the stock had climbed to $7.65.
Top-line data from the phase II Kickstart study of Effector Therapeutics Inc.’s tomivosertib as a frontline treatment of non-small-cell lung cancer failed to produce data strong enough to continue development in the indication. The company has decided to halt the study, move ahead with a separate, investigator-sponsored study of tomivosertib in acute myeloid leukemia and focus on another drug in its pipeline for treating breast cancer. Effector’s stock (NASDAQ:EFTR) crumpled on the NCSLC news as shares plunged 82% on April 4 to close at $2.96 each. The closing value was the lowest the company has seen in the past 12 months.
Bridge Medicines LLC has divulged protein ENL (MLLT1; YEATS1) and/or FLT3 (FLK2/STK1) inhibitors potentially useful for the treatment of acute lymphocytic leukemia and acute myeloid leukemia.
Ono Pharmaceutical Co Ltd. has identified diacylglycerol kinase α (DGK-α, DGKA) and/or diacylglycerol kinase ζ (DGK-ζ, DGKZ) inhibitors reported to be useful for the treatment of cancer.
RSS
